Browse EX-10 agreements

1 FULTON FINANCIAL CORPORATION Time-Vested Restricted Stock Unit Award Agreement (this “Award Agreement”) [GRANT DATE] [PARTICIPANT NAME] [HOME ADDRESS] Dear [PARTICIPANT NAME]: Pursuant to the terms and conditions of the 2022 Amended and Restated Equity and Cash Incentive Compensation Plan (the “2022 Plan”) of Fulton Financial Corporation (“Fulton”), you are the recipient of a time-vested Restricted Stock Unit (“RSU”) award (the “Award”). The Award has the following terms and conditions as of the Date of Grant. Capitalized terms used herein but not defined shall have the meanings set forth in the 2022 Plan. Granted To: [PARTICIPANT NAME] Date of Grant: [GRANT DATE] Number of Time-Vested RSUs Granted: [TOTAL AWARDS] Awards are calculated using the 20- trading day average closing stock price of Fulton’s common stock prior to the Date of Grant. Restricted Period: Unless the Award is forfeited before the end of the Restricted Period, the Restricted Period will end three years after the Date of Grant. Retirement: Upon your Retirement as defined in the 2022 Plan, the forfeiture res

…

1 FULTON FINANCIAL CORPORATION Non-Employee Director Stock Unit Award Agreement (“Award Agreement”) [GRANT DATE] [PARTICIPANT NAME] [HOME ADDRESS] Dear [PARTICIPANT NAME]: Pursuant to the terms and conditions of the Amended and Restated 2023 Director Equity Plan (the “2023 Plan”) of Fulton Financial Corporation (“Fulton”), you are the recipient of a Restricted Stock Unit (“RSU”) award (the “Award”). The Award has the following terms and conditions as of the Date of Grant. Capitalized terms used herein but not defined shall have the meanings set forth in the 2023 Plan. Granted To: [PARTICIPANT NAME] Date of Grant: [GRANT DATE] Number of Time-Vested RSUs Granted: [TOTAL AWARDS] Awards are calculated using the 20-trading day average closing stock price of Fulton’s common stock prior to the Date of Grant. Restricted Period: Unless your Award is forfeited before the end of the Restricted Period, the Restricted Period will end one year after the Date of Grant. Death, Disability or Retirement: Your Award will vest and Shares will be delivered to you upon your death, Disability or Ret

…

1 FULTON FINANCIAL CORPORATION Performance Restricted Stock Unit Award Agreement (this “Award Agreement”) [GRANT DATE] [PARTICIPANT NAME] [HOME ADDRESS] Dear [PARTICIPANT NAME]: Pursuant to the terms and conditions of the 2022 Amended and Restated Equity and Cash Incentive Compensation Plan (the “2022 Plan”) of Fulton Financial Corporation (“Fulton”), you are the recipient of a Performance Share Award (the “Award”) in the form of performance-based restricted stock units (“PRSUs”). The Award has the following terms and conditions as of the Date of Grant. Capitalized terms used herein but not defined shall have the meanings set forth in the 2022 Plan. Participant: [PARTICIPANT NAME] Date of Grant: [GRANT DATE] Aggregate Total PRSUs for TSR Performance: [TOTAL AWARDS] (at target for TSR) Awards are calculated using the 20-trading day average closing stock price of Fulton’s common stock prior to the Date of Grant. Range of Potential PRSUs as a Percentage of Target: 0.00% to 150.00% of target (determined on the Vest Date). Performance Period: May 1, 2026 to March 31, 2029 Performan

…

May 29, 2026

Via Email

Bret Christensen

Dear Bret:

Thank you again for your service to BioTE Medical, LLC (the “Company”). This letter sets forth the substance of your voluntary resignation and the separation of your employment from the Company (the “Agreement”).

1.

Separation. Your last day of work with the Company and your employment termination date will be June 8, 2026 (the “Separation Date”).

2.

Accrued Compensation. In the next scheduled payroll cycle after the Separation Date, the Company will pay you all accrued salary and all accrued and unused vacation/PTO earned through the Separation Date, subject to standard payroll deductions and withholdings. You will receive your accrued but unpaid compensation regardless of whether you sign this Agreement.

3.

…

biote Corp.

Non-Employee Director Compensation Policy

Each member of the Board of Directors (the “Board”) of biote Corp. (the “Company”) who is a non-employee director of the Company or any of its subsidiaries (each, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for Board service upon and following January 1, 2025 (the “Effective Date”).

An Eligible Director may decline all or any portion of such compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be, subject to compliance with applicable tax laws.

This Policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board.

Annual Cash Compensation

The annual cash compensation set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred.

…

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Robert Peterson (“Executive”) and BioTE Medical, LLC (the “Company”), and effective as of June 8, 2026 (“Effective Date”). Subject to Section 7.4, this Agreement supersedes and replaces the Employment Agreement between the Company and Executive, entered into effective January 8, 2024 (the “Prior Agreement”).

WHEREAS, Executive shall be employed by the Company as its Interim Chief Executive Officer (“InterimCEO”);

WHEREAS, the Company desires to employ Executive and, in connection therewith, to compensate

Executive for Executive’s personal services to the Company from and after the Effective Date; and

WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation.

Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:

1.

Employment by the Company.

1.1

…

AMENDED AND RESTATED SERVICES AGREEMENT

This AMENDED AND RESTATED SERVICES AGREEMENT (the “Agreement”) is entered into by and between Marc Beer (“Chairman”) and BioTE Medical, LLC (the “Company”), and effective as of June 8, 2026 (“Effective Date”). [This Agreement supersedes and replaces the Services Agreement between the Company and Chairman, entered into effective [June 14, 2022] (the “Prior Agreement”).]

WHEREAS, Chairman is engaged to provide services to the Company as its Executive Chairman;

WHEREAS, the Company desires that Chairman continue to provide services to the Company and its affiliates and, in connection therewith, to compensate Chairman for Chairman’s personal services to the Company from and after the Effective Date; and

WHEREAS, Chairman wishes to continue to provide services to the Company and its affiliates and provide personal services to the Company and its affiliates in return for certain compensation.

Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:

1.

…

LIMITEDCONDITIONALWAIVERANDCONSENTAGREEMENT

ThisLIMITEDCONDITIONALWAIVERANDCONSENTAGREEMENT(this“Agreement”),

dated as of June 30, 2026, is among the UNITED STATES DEPARTMENT OF ENERGY, an agency of the United States of America (“DOE”); MONTANA RENEWABLES, LLC, a limited liability company organized and existing under the laws of the State of Delaware (the “Borrower”); MONTANA RENEWABLES HOLDINGS LLC., a limited liability company organized and existing under the laws of theStateofDelaware(the“DirectParent”);CALUMET,INC.,acorporationorganizedandexistingunder the laws of the State of Delaware (the “Calumet Parent”); WPGG 14 UNITED AGGREGATOR, L.P., a limitedpartnershiporganizedandexistingunderthelawsoftheStateofDelaware(togetherwiththeDirect Parentandthe Calumet Parent,the“Sponsors”,andeacha“Sponsor”); andCITIBANK,N.A.,a national bankingassociationactingthroughitAgencyandTrustbusiness,ascollateralagent(“CollateralAgent”).

…

AMENDMENT NO. 1

TO THE CERVOMED INC.

2025 EQUITY INCENTIVE PLAN

This AMENDMENT NO. 1 TO THE CERVOMED INC. 2025 EQUITY INCENTIVE PLAN (this “Amendment”) is made as of June 8, 2026.

Pursuant to Section 19 of the CervoMed Inc. 2025 Equity Incentive Plan (the “Plan”), the Plan is hereby amended as follows:

1.     Effective upon the approval of the holders of at least a majority of the outstanding shares of stock of CervoMed Inc. (the “Company”) entitled to vote at the Company’s 2026 Annual Meeting of Stockholders, Section 4.1 of the Plan is hereby deleted and replaced in its entirety by the following:

“4.1     Maximum Number of Shares Available.  Certain Restrictions on Awards.  Subject to adjustment as provided in Section 4.3 of the Plan, the maximum number of shares of Common Stock that will be available for issuance under the Plan will be the sum of:

(a)     2,800,000 (the “Base Amount”);

…

GLOBAL RSU FORM

Exhibit 10.2

DARLING INGREDIENTS INC.

2026 Omnibus Incentive Plan

Notice of Restricted Stock Unit Grant

Grantee:             ____________________

Restricted Stock Units:    You have been awarded a restricted stock unit award with respect to ________ shares of common stock, par value $0.01 per share, of the Company, subject to adjustment as provided in the Plan.

Grant Date:            ____________________

Vesting Commencement Date:    One-year anniversary of the Grant Date

Vesting Schedule:    Except as set forth in the Agreement, this award shall vest in accordance with the following schedule, subject to the Grantee’s continued Service with the Company as of the applicable vesting date:

…

GLOBAL FORM

Exhibit 10.1

DARLING INGREDIENTS INC.

PERFORMANCE UNIT AWARD AGREEMENT

SECTION 1.     GRANT OF AWARD.

On the terms and conditions set forth in this Performance Unit Award Agreement, including Appendix A and Battached hereto (together with any applicable terms contained in any other Addendum hereto, this “Agreement”), Darling Ingredients Inc. (the “Company”) hereby grants to the undersigned individual (the “Grantee”) performance-based restricted stock units (the “Performance Units”) as specified below, each of which represents a contingent right to acquire a share of common stock of the Company, $0.01 par value per share (a “Share”) at a future date after such Performance Unit has become vested, with a target opportunity equal to _________ Performance Units (the “Target Award”).

This award is granted under and subject to the terms of the Darling Ingredients Inc. 2026 Omnibus Incentive Plan (the “Plan”), which is incorporated herein by this reference. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Plan.

…

Effective May 7, 2026

Exhibit 10.3

DARLING INGREDIENTS INC.

Non-Employee Director Compensation Program

1.Purpose. This Non-Employee Director Compensation Program (the “Program”) is adopted by the Board of Directors (the “Board”) of Darling Ingredients Inc. (the “Company”). This Program is adopted pursuant to the Darling Ingredients Inc. 2026 Omnibus Incentive Plan (the “2026 Plan”). Capitalized terms defined in the 2026 Plan that are used herein without being defined shall have the same meanings as set forth in the 2026 Plan.

2.Participants. Each Non-Employee Director shall participate in the Program (each, a “Participant”).

3.Restricted Stock Units.

3.1Grant.

…